DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy

被引：23

作者：

Argyrakopoulou, Georgia ^{[2
]}

Doupis, John ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA

[2] Kapodistriakon Univ, Sch Med, Laikon Hosp, Athens, Greece

来源：

ADVANCES IN THERAPY | 2009年 / 26卷 / 03期

关键词：

alogliptin; diabetes mellitus; DPP4; inhibitors; incretin; metformin; pioglitazone; saxagliptin; sitagliptin; vildagliptin; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; GLUCAGON-LIKE PEPTIDE-1; IMPROVES GLYCEMIC CONTROL; DRUG-NAIVE PATIENTS; DEPENDENT INSULINOTROPIC POLYPEPTIDE; BETA-CELL FUNCTION; DOUBLE-BLIND; RENAL-INSUFFICIENCY; INCRETIN HORMONES; DIABETIC-PATIENTS;

D O I：

10.1007/s12325-009-0009-6

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

100103 [病原生物学]; 100218 [急诊医学];

摘要：

Diabetes mellitus (DM) is currently considered to be an epidemic disease. A safe and effective treatment has long been sought by scientists. Incretin mimetics and dipeptidyl peptidase-4 (DPP4) inhibitors represent a new class of agents that have recently been included as antidiabetic drugs. Although only a limited number of studies exist regarding the treatment of DM based on the incretin effect, DPP4 inhibitors have so far proved to be safe and effective, both when administered alone or in combination with other antidiabetic medication. This review focuses on incretin-effect physiology, as well as the DPP4 inhibitors, from sitagliptin to the new alogliptin-pioglitazone combination agent, given as monotherapy and in combination with other antidiabetic agents.

引用

页码：272 / 280

页数：9

共 47 条

[1]

The inhibitory effects of peripheral administration of peptide YY3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway [J].

Abbott, CR ;

Monteiro, M ;

Small, CJ ;

Sajedi, A ;

Smith, KL ;

Parkinson, JRC ;

Ghatei, MA ;

Bloom, SR .

BRAIN RESEARCH, 2005, 1044 (01) :127-131

[2]

Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year [J].

Ahrén, B ;

Pacini, G ;

Foley, JE ;

Schweizer, A .

DIABETES CARE, 2005, 28 (08) :1936-1940

[3]

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes [J].

Ahrén, B ;

Landin-Olsson, M ;

Jansson, PA ;

Svensson, M ;

Holmes, D ;

Schweizer, A .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2078-2084

[4]

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [J].

Aschner, Pablo ;

Kipnes, Mark S. ;

Lunceford, Jared K. ;

Sanchez, Matilde ;

Mickel, Carolyn ;

Williams-Herman, Debora E. .

DIABETES CARE, 2006, 29 (12) :2632-2637

[5]

Biology of incretins: GLP-1 and GIP [J].

Baggio, Laurie L. ;

Drucker, Daniel J. .

GASTROENTEROLOGY, 2007, 132 (06) :2131-2157

[6]

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor [J].

Bergman, Arthur J. ;

Cote, Josee ;

Yi, Bingming ;

Marbury, Thomas ;

Swan, Suzanne K. ;

Smith, William ;

Gottesdiener, Keith ;

Wagner, John ;

Herman, Gary A. .

DIABETES CARE, 2007, 30 (07) :1862-1864

[7]

Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study [J].

Bolli, G. ;

Dotta, F. ;

Rochotte, E. ;

Cohen, S. E. .

DIABETES OBESITY & METABOLISM, 2008, 10 (01) :82-90

[8]

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin [J].

Bosi, Emanuele ;

Camisasca, Riccardo Paolo ;

Collober, Carole ;

Rochotte, Erika ;

Garber, Alan J. .

DIABETES CARE, 2007, 30 (04) :890-895

[9]

The glucagon-like peptides - Pleiotropic regulators of nutrient homeostasis [J].

Brubaker, Patricia L. .

VIP, PACAP, AND RELATED PEPTIDES: FROM GENE TO THERAPY, 2006, 1070 :10-26

[10]

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [J].

Charbonnel, Bernard ;

Karasik, Avraham ;

Liu, Ji ;

Wu, Mei ;

Meininger, Gary .

DIABETES CARE, 2006, 29 (12) :2638-2643

← 1 2 3 4 5 →